Gerald V Naccarelli

List of Publications by Year
in descending order

114 papers	3,850 citations	270111 25 h-index	145109 60 g-index
119 all docs	119 docs citations	119 times ranked	5056 citing authors

#	Article	IF	Citations
1	Pulmonary vein isolation with adjunctive left atrial ganglionic plexus ablation for treatment of atrial fibrillation: a meta-analysis of randomized controlled trials. Journal of Interventional Cardiac Electrophysiology, 2023, 66, 333-342.	0.6	9
2	Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies. Clinical Cardiology, 2022, 45, 119-128.	0.7	0
3	Assessment of Comorbidity Burden and Treatment Response: Reanalysis of the SCD-HEFT Trial. Drugs and Aging, 2022, 39, 165-173.	1.3	3
4	The Increasing Role of Rhythm Control in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1932-1948.	1.2	63
5	Women and atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2021, 32, 2793-2807.	0.8	39
6	Leaps and Gaps in Transcatheter Aortic Valve Replacement Management. Circulation: Cardiovascular Interventions, 2021, 14, e010719.	1.4	0
7	Oral Anticoagulation Use in High-Risk Patients Is Improved by Elimination of False-Positive and Inactive Atrial Fibrillation Cases. American Journal of Medicine, 2021, 134, e366-e373.	0.6	4
8	Abnormal P-wave terminal force in lead V1 is associated with low left atrial appendage ejection velocity. Journal of Electrocardiology, 2021, 67, 142-147.	0.4	2
9	Do Mineralocorticoid Receptor Antagonists Suppress AtrialÂFibrillation/Flutter?. Journal of the American College of Cardiology, 2021, 78, 153-155.	1.2	3
10	Association Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressureâ€“Lowering Therapy. JAMA Network Open, 2021, 4, e2128980.	2.8	9
11	Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valvesâ€”A Systematic Review and Meta-analysis. Journal of Innovations in Cardiac Rhythm Management, 2021, 12, 4797-4805.	0.2	0
12	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. American Heart Journal, 2020, 220, 145-154.	1.2	3
13	Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation. American Heart Journal, 2020, 219, 21-30.	1.2	8
14	Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). American Journal of Cardiology, 2020, 132, 66-71.	0.7	1
15	A Multimorbidity-Based, Risk-Stratified Reanalysis of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Trial. Drugs and Aging, 2020, 37, 839-844.	1.3	5
16	Outcomes Associated with Dronedarone Use in Patients with Atrial Fibrillation. American Journal of Cardiology, 2020, 135, 77-83.	0.7	7
17	Direct Oral Anticoagulant Dosing. Journal of the American College of Cardiology, 2020, 76, 1437-1439.	1.2	5
18	Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2020, 13, e007775.	2.1	6

#	Article	IF	Citations
19	Evaluation of the Switch From Amiodarone to Dronedarone in Patients With Atrial Fibrillation: Results of the ARTEMIS AF Studies. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 425-437.	1.0	1
20	Rhythm Control of Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction. Current Cardiology Reports, 2020, 22, 83.	1.3	3
21	Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials. Journal of Cardiovascular Electrophysiology, 2020, 31, 1022-1030.	0.8	3
22	Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Heart, 2020, 106, 358-364.	1.2	16
23	B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation. Heart, 2019, 105, heartjnl-2018-313642.	1.2	22
24	A Quarter of a Century Later: What is Dofetilideâ€™s Clinical Role Today?. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 3-10.	1.0	14
25	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	3.0	10
26	Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. American Heart Journal, 2019, 213, 81-90.	1.2	10
27	Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005358.	0.9	59
28	Meta-Analysis of Atrial Fibrillation Ablation in Patients with Systolic Heart Failure. Cardiovascular Therapeutics, 2019, 2019, 1-10.	1.1	10
29	Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2019, 321, 1261.	3.8	953
30	Antiarrhythmic Drugs for AtrialÂFibrillation in the Real World. JACC: Clinical Electrophysiology, 2019, 5, 242-244.	1.3	2
31	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	1.2	8
32	Risk Factors for Symptomatic Atrial Fibrillation-Analysis of an Outpatient Database. Journal of Atrial Fibrillation, 2019, 12, 2141.	0.5	5
33	Relation of Obesity to New-Onset Atrial Fibrillation and Atrial Flutter in Adults. American Journal of Cardiology, 2018, 121, 1072-1075.	0.7	39
34	Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation. Circulation, 2018, 138, 889-897.	1.6	23
35	Catheter Ablation in Children With Accessory A-V Pathway. JACC: Clinical Electrophysiology, 2018, 4, 456-458.	1.3	0
36	Percutaneous left atrial appendage closure is not ready for routine clinical use. Heart Rhythm, 2018, 15, 298-301.	0.3	32

#	Article	IF	Citations
37	Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes. JAMA Cardiology, 2018, 3, 54.	3.0	77
38	Screening for Atrial Fibrillation Comes With Many Snags. JAMA Internal Medicine, 2018, 178, 1296.	2.6	19
39	Can an Intranasal Calcium-Channel Blocker Convert Paroxysmal Supraventricular Tachycardia and Keep the Doctor Away?. Journal of the American College of Cardiology, 2018, 72, 498-500.	1.2	2
40	Cardiac automaticity: basic concepts and clinical observations. Journal of Interventional Cardiac Electrophysiology, 2018, 52, 263-270.	0.6	13
41	Periprocedural Use of Oral Anticoagulation Therapy in Patients Undergoing Atrial Fibrillation Ablation. Journal of Innovations in Cardiac Rhythm Management, 2018, 9, 3274-3281.	0.2	1
42	International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. American Heart Journal, 2017, 194, 132-140.	1.2	161
43	Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines. Circulation: Arrhythmia and Electrophysiology, 2017, 10, .	2.1	29
44	Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	0
45	Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men. JAMA Cardiology, 2016, 1, 282.	3.0	182
46	Patient factors associated with quality of life in atrial fibrillation. American Heart Journal, 2016, 182, 135-143.	1.2	62
47	Bramah N. Singh, MD, DPhil, DSc: A Tribute. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 342-343.	1.0	0
48	Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. European Heart Journal, 2015, 36, 1805-1811.	1.0	370
49	New Oral Anticoagulants. Medical Clinics of North America, 2015, 99, 759-780.	1.1	5
50	Surface 12 lead electrocardiogram recordings using smart phone technology. Journal of Electrocardiology, 2015, 48, 1-7.	0.4	44
51	Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease. Europace, 2014, 16, 153-155.	0.7	0
52	An atypical case of vagally mediated atrial fibrillation in an elderly woman: Electrocardiographic caveats to diagnosis. Journal of Electrocardiology, 2014, 47, 734-737.	0.4	5
53	Rationale and design of VENTURE-AF: a randomized, open-label, active-controlled multicenter study to evaluate the safety of rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2014, 41, 107-116.	0.6	16
54	Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry. Circulation, 2014, 130, .	1.6	0

#	Article	IF	Citations
55	Catheter ablation of atrial fibrillation: the need for studies to assess the efficacy and safety of novel anticoagulants. Journal of Interventional Cardiac Electrophysiology, 2013, 36, 3-4.	0.6	5
56	Appropriate and Inappropriate Use of Dronedarone in 2013. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 467-475.	0.4	3
57	Rates and Implications for Hospitalization of Patients â‰¥65 Years of Age With Atrial Fibrillation/Flutter. American Journal of Cardiology, 2012, 109, 543-549.	0.7	43
58	CHADS2 and CHA2DS2-VASc Risk Factors to Predict First Cardiovascular Hospitalization Among Atrial Fibrillation/Atrial Flutter Patients. American Journal of Cardiology, 2012, 109, 1526-1533.	0.7	61
59	Post-ATHENA and beyond. Journal of Interventional Cardiac Electrophysiology, 2011, 31, 55-60.	0.6	2
60	Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter. Clinical Medicine Insights: Cardiology, 2011, 5, CMC.S6677.	0.6	33
61	Cost Burden of Cardiovascular Hospitalization and Mortality in ATHENAâ€Like Patients With Atrial Fibrillation/Atrial Flutter in the United States. Clinical Cardiology, 2010, 33, 270-279.	0.7	57
62	Practice Patterns Among United States Cardiologists for Managing Adults With Atrial Fibrillation (from the AFFECTS Registry). American Journal of Cardiology, 2010, 105, 1122-1129.	0.7	45
63	Warfarin and Aspirin Use in Atrial Fibrillation Among Practicing Cardiologist (from the AFFECTS) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.7	30
64	A Review of the Appropriate and Inappropriate Use of Dronedarone: Lessons Learned From Controlled Studies and Regulatory Submission. Journal of Cardiovascular Pharmacology and Therapeutics, 2010, 15, 24S-30S.	1.0	7
65	Increasing Prevalence of Atrial Fibrillation and Flutter in the United States. American Journal of Cardiology, 2009, 104, 1534-1539.	0.7	746
66	Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devices. Clinical Cardiology, 2009, 28, 51-57.	0.7	2
67	Vernakalant â€“ a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opinion on Investigational Drugs, 2008, 17, 805-810.	1.9	24
68	Atrial Fibrillation and the Expanding Role of Catheter Ablation: Do Antiarrhythmic Drugs Have a Future?. Journal of Cardiovascular Pharmacology, 2008, 52, 203-209.	0.8	15
69	Vernakalant: Pharmacology, electrophysiology, safety and efficacy. Drugs of Today, 2008, 44, 325.	0.7	13
70	New antiarrhythmic treatment of atrial fibrillation. Expert Review of Cardiovascular Therapy, 2007, 5, 707-714.	0.6	22
71	Antiarrhythmic drug therapy for atrial fibrillation: Are the guidelines guiding clinical practice?. Clinical Cardiology, 2006, 29, 97-102.	0.7	22
72	Cardiac Implantable Electrical Devices in the Elderly: A Promise of Prolonged Survival and an Improved Quality of Life. The American Journal of Geriatric Cardiology, 2006, 15, 75-76.	0.7	0

#	Article	IF	Citations
73	Carvedilol's antiarrhythmic properties: Therapeutic implications in patients with left ventricular dysfunction. Clinical Cardiology, 2005, 28, 165-173.	0.7	28
74	Antiadrenergic Therapy in the Control of Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics, 2005, 10, S33-S43.	1.0	4
75	Does carvedilol have antiarrhythmic properties?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 338-339.	3.3	1
76	Advances in the Treatment of Atrial Fibrillation: The Future is Now. Journal of Interventional Cardiac Electrophysiology, 2004, 10, 77-78.	0.6	1
77	Does it make sense to train plumbers as electricians?. Journal of the American College of Cardiology, 2004, 44, 1358-1360.	1.2	15
78	Implantable cardioverter-defibrillators: expanding indications. Current Opinion in Cardiology, 2004, 19, 317-322.	0.8	2
79	A review of clinical trials assessing the efficacy and safety of newer antiarrhythmic drugs in atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2003, 9, 215-222.	0.6	26
80	Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. American Journal of Cardiology, 2003, 91, 15-26.	0.7	156
81	Atrial Fibrillation in Heart Failure:. Journal of Cardiovascular Electrophysiology, 2003, 14, S281-S286.	0.8	41
82	The Brugada syndrome. Current Opinion in Cardiology, 2002, 17, 19-23.	0.8	22
83	Maintaining stability of sinus rhythm in atrial fibrillation: Antiarrhythmic drugs versus ablation. Current Cardiology Reports, 2002, 4, 418-425.	1.3	2
84	Reprocessing of Electrophysiology Catheters: Clinical Studies, Regulations, and Recommendations. A Report of the NASPE Task Force on Reprocessing of Electrophysiological Catheters. PACE - Pacing and Clinical Electrophysiology, 2001, 24, 1297-1305.	0.5	10
85	Electrocardiography of Clinical Arrhythmias. Circulation, 2001, 104, .	1.6	0
86	Amiodarone: What have we learned from clinical trials?. Clinical Cardiology, 2000, 23, 73-82.	0.7	33
87	Can Electrophysiologists Survive the New Era of Health Care Reform?. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 2008-2011.	0.5	1
88	Optimization of Defibrillation Function. , 0, , 197-205.		0
89	Advances in Catheter Control Devices. , 0, , 257-261.		0
90	Implantable Defibrillator Sensing and Discrimination Algorithms. , 0, , 161-177.		1

#	Article	IF	Citations
91	Epicardial Access: Present and Future Applications for Interventional Electrophysiologists. , 0, , 242-256.		0
92	Sensor and Sensor Integration. , 0, , 109-118.		0
93	New Ablation Paradigms: Anatomic Ablation of Complex Arrhythmia Substrates. , 0, , 274-281.		0
94	Advances in Energy Sources in Catheter Ablation. , 0, , 262-273.		1
95	Arrhythmia Prevention and Termination Algorithms. , 0, , 178-186.		0
96	New Lead Designs and Lead-less Systems. , 0, , 187-196.		0
97	New Frontiers in Antithrombotic Therapy for Atrial Fibrillation. , 0, , 14-28.		0
98	Embryonic Stem-cell-derived Cardiomyocytes as a Model For Arrhythmia. , 0, , 48-53.		0
99	New Indications for Pacing. , 0, , 154-160.		0
100	Beta-blocker Efficacy in Long-QT Syndrome Patients with Mutations in the Pore and Nonpore Regions of the hERG Potassium-channel Gene. , 0, , 91-94.		0
101	New Electrode and Lead Designs for Pacemakers. , 0, , 119-123.		0
102	New Resynchronization Lead Systems and Devices. , 0, , 145-153.		3
103	Gene Therapy for Cardiac Tachyarrhythmias. , 0, , 65-71.		0
104	Techniques of Prediction of Arrhythmia Occurrence and Stratification for Sudden Cardiac Death. , 0, , 84-90.		0
105	New ICD Indications. , 0, , 219-229.		0
106	Advances in Surgical Ablation Devices for Atrial Fibrillation. , 0, , 231-241.		8
107	New Developments in Noninvasive Rhythm Monitoring, Implantable Hemodynamic Monitoring, Functional Status Monitoring, and Noninvasive Mapping. , 0, , 73-83.		0
108	Left Ventricular Epicardial Lead Implantation: Anatomy, Techniques, and Tools. , 0, , 134-144.		0

#	Article	IF	Citations
109	The Cardiac Sodium-Channel Carboxy Terminus: Predicted and Detected Structure Provide a Novel Target For Antiarrhythmic Drugs Development. , 0, , 36-47.		0
110	Current Concepts in Intravascular Pacemaker and Defibrillator Lead Extraction. , 0, , 124-133.		2
111	New Developments in Out-of-hospital Cardiac Defibrillation: Evaluation of AED Strategies. , 0, , 95-108.		0
112	Remote Web-based Device Monitoring. , 0, , 206-218.		0
113	Principles of Pharmacogenomics: Focus on Arrhythmias. , 0, , 29-35.		0
114	Gene and Cell Therapy for Sinus and AV Nodal Dysfunction. , 0, , 54-64.		0